American Heart Journal
Volume 149, Issue 5 , Pages 820-825 , May 2005

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients

  • Emiliana Ferramosca, MD

      Affiliations

    • Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, La
    • ,
  • Steven Burke, MD

      Affiliations

    • Drug Discovery and Development, Genzyme Therapeutics, Waltham, Mass
    • ,
  • Scott Chasan-Taber, PhD

      Affiliations

    • Pioneer BioDiligence, Amherst, Mass
    • ,
  • Carlo Ratti, MD

      Affiliations

    • Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, La
    • ,
  • Glenn M. Chertow

      Affiliations

    • Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, Calif
    • ,
  • Paolo Raggi, MD

      Affiliations

    • Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, La
    • Corresponding Author InformationReprint requests: Paolo Raggi, MD, Tulane University School of Medicine, 1430 Tulane Avenue, SL48, New Orleans, LA 70112.

Received 19 April 2004 ,Accepted 27 July 2004.

References 

  1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998;32(Suppl. 3):S112–S119
  2. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol. Dial. Transplant. 2000;15:S58–S68
  3. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 1999;340:115–126
  4. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin. Dial. 2002;15:329–337
  5. Wanner C, Zimmermann J, Schwedler S, et al. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. Suppl. 2002;80:99–102
  6. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  7. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. Kidney Int. 2001;59:407–414
  8. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627–636
  9. Undas A, Brozek J, Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin. Lab. 2002;48:287–296
  10. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 2001;344:1959–1965
  11. van den Akker JM, Bredie SJ, Diepenveen SH, et al. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J. Nephrol. 2003;16:238–244
  12. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297–304
  13. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998;31:607–617
  14. De Boer IH, Gorodetskaya I, Young B, et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J. Am. Soc. Nephrol. 2002;13:2762–2769
  15. Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  16. Chertow GM, Burke SK, Dillon MA, et al. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol. Dial. Transplant. 1999;14:2907–2914
  17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499–502
  18. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J. Am. Coll. Cardiol. 1990;15:827–832
  19. Callister TQ, Cooil B, Raya SP, et al. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology. 1998;208:807–814
  20. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J. Am. Soc. Nephrol. 2002;13:1918–1927
  21. Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin. Dial. 2003;16:118–127
  22. Mallamaci F, Tripepi G, Maas R, et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2004;15:435–441
  23. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 1999;10:594–600
  24. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138–141
  25. Scholze A, Rinder C, Beige J, et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004;109:369–374
  26. Longenecker JC, Klag MJ, Marcovina SM, et al. Choices for Healthy Outcomes in Caring for ESRD. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation. 2002;106:2812–2818
  27. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003;18:1731–1740
  28. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434–2439
  29. K-DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003;42(Suppl. 3):S1–S201
  30. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 2000;87:E10–E17
  31. Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am. J. Kidney Dis. 2000;43:572–579
  32. Kurz P, Moniere-Faugere M-C, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46:855–861
  33. Freemont T. Histological diagnosis of renal osteodystrophy. Kidney Int. 1999;56:S26–S30
  34. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol. Dial. Transplant. 2000;15:218–223
  35. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 2003;18:1731–1740
  36. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int. 2002;62:611–619
  37. Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955–1961
  38. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–484
  39. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur. Heart J. 1998;19:A40–A44
  40. Quaschning T, Krane V, Metzger T, et al. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am. J. Kidney Dis. 2001;38(4, Suppl. 1):S14–S19
  41. Shoji T, Nishizawa Y, Kawagishi T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J. Am. Soc. Nephrol. 1998;9:1277–1284
  42. De Smet R, Thermote F, Lameire N, et al. Sevelamer hydrochloride (Renagel) adsorbs the uremic compound indoxyl sulfate. J. Am. Soc. Nephrol. 2003;14:206A

PII: S0002-8703(04)00459-4

doi: 10.1016/j.ahj.2004.07.023

American Heart Journal
Volume 149, Issue 5 , Pages 820-825 , May 2005

Article Tools